Numbers don’t lie

Numbers don’t lie

Not like we needed even more evidence that Lilly is now a GLP-1 first insulin second company here are some numbers from today’s earnings release all of which are year to date sales

Trulicity $2.98 Billion

Humalog $1.2 Billion

Humulin $637 million

Basaglar $457 million

Sales of the three insulin products added together still do not match what Trulicity is doing. Want more reasons why GLP-1’s are getting all the attention and not just because sales are increasing, patent life is longer and commodization has yet to occur – take a look at . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.